Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.
How it works
A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.
Analysis and opinion covers key topic areas such as:
Generics Bulletin
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
Generics Bulletin
The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.
HBW Insight, Generics Bulletin, Medtech Insight, Datamonitor...
Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Now you can listen to our podcasts on subjects you choose, right from your Alexa smartphone app!
Generics Bulletin
World Health Organization recommendations to use dexamethasone and hydrocortisone to treat patients with severe and critical COVID-19 demonstrate the potential for common and low-cost generics in fighting the coronavirus pandemic.
Topic Coronavirus
Generics Bulletin
Guidance from the UK’s MHRA on post-Brexit arrangements relevant to the off-patent industry has been welcomed by local industry body the BGMA. However, it has warned that time is short to prepare for the end of the UK-EU transition period, with new guidance in certain areas “critical.”
Topic Brexit
Generics Bulletin
The Annual Top 50 Generics & Biosimilars Companies League Table is here, and Generics Bulletin is sharing its content with you! Connect to league tables and commentary summarizing key developments for the Top 10 companies in generics and biosimilars, part of Generics Bulletin’s annual Top 50 ranking.
Topic Biosimilars
Generics Bulletin
In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.
Topic Coronavirus Manufacturing
Generics Bulletin
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
Topic Coronavirus Distribution
Generics Bulletin
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Topic Coronavirus
Generics Bulletin
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
Generics Bulletin
Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.
Generics Bulletin
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Topic Coronavirus Drug Review
Generics Bulletin
Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.
Topic Coronavirus
Generics Bulletin
C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.
Topic Coronavirus
Generics Bulletin
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.
Topic Coronavirus
Generics Bulletin
30 Sep 2020
Generics Bulletin
30 Sep 2020
Generics Bulletin
30 Sep 2020
Generics Bulletin
30 Sep 2020
Generics Bulletin
30 Sep 2020
Generics Bulletin
30 Sep 2020
Generics Bulletin
29 Sep 2020
Generics Bulletin
29 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
28 Sep 2020
Generics Bulletin
25 Sep 2020
Generics Bulletin
25 Sep 2020
UK
Aidan specializes in
+22 year(s) experience
UK
Duncan specializes in
+20 year(s) experience
UK
Andrea specializes in
+17 year(s) experience
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Successfully navigate the complex worlds of compliance, legislation, policy regulation, and industry developments with the expertise of our worldwide network of expert analysts and journalists.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
